<style face="normal" font="default" size="100%">1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors</style>

Drupal-HighWire